Eder P, Reinprecht I, Schreiner E, Skofitsch G, Windisch M.

Increased density of glutamate receptor subunit 1 due to Cerebrolysin treatment: an immunohistochemical study on aged rats.

Histochem J 2001;33(11-12):605-612.

Fei Z, Yi S.

Change of free radicals in the plasma of patients with cranio-cerebral trauma and therapeutical effect of Cerebrolysin.

Chin J Nerv Ment Dis 1992:18/6.

Francis-Turner L, Valouskova V.

Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria- fornix transection: short-term study.

Neurosci Lett 1996;202(3):193-196.

Funke M, Fieler J, Mewes I. Eiselt M, Rother I, Windisch M.

Dose-dependent effects of Cerebrolysin on short-term memory of healthy volunteers during control and hyperventilation induced cerebral ischemia.

J Neural Transm Suppl 1998;53:385-398.

Gonzalez ME, Francis L, Castellano O.

Antioxidant systemic effect of short-term Cerebrolysin administration. J Neural Transm Suppl 1998;53:333-341.

Gorbachevskaya N, Bashina V, Gratchev V, Iznak A.

Cerebrolysin therapy in Rett syndrome: clinical and EEG mapping study. Brain Dev 2001;23 Suppl 1:S90-S93.

Grundman M, Corey-Bloom J, Thal LJ.

Perspectives in clinical Alzheimer's disease research and the develop-ment of antidementia drugs. J Neural Transm Suppl 1998;53:255-275.

Gschanes A, Boado R, Sametz W, Windisch M.

The cerebrolysin and its peptide fraction E021 increase the abundance of the blood-brain barrier GLUT1 glucose transporter in brains of young and old rats.

Histochem J 2000;32(2):71-77.

Gschanes A, Valouskova V, Windisch M.

Ameliorative influence of a nootropic drug on motor activity of rats after bilateral carotid artery occlusion.

J Neural Transm 1997;104(11-12):1319-1327.

Gschanes A, Windisch M.

The influence of Cerebrolysin and E021 on spatial navigation of 24-month-old rats. J Neural Transm Suppl 1998;53:313-321.

Gschanes A, Windisch M.

Early postnatal treatment with peptide preparations influences spatial navigation of young and adult rats.

Behav Brain Res 1999;100(1-2):161-166.

Gutman B, Hutter-Paier B, Skofitsch G, Windisch M, Gmeinbauer R.

In vitro models of brain ischemia: the peptidergic drug Cerebrolysin protects chick cortical neurons from cell death.

Neurotoxity Res 2002; 4(1):59-65.

Haffner Z, Javor L, Windisch M, Gmeinbauer R.

Cerebrolysin in acute ischemic stroke. Cephallag Hungr 1999;5:52-53.

Hanines P, Houst’ava L, Stejkal L, Dubovy P.

Rescue of rat spinal motoneurons from avulsion-induced cell death by intrathecal adminisytation of IGF-I and Cerebrolysin. Ann Anat 2003;185(3):233-238.

Hartbauer M, Hutter-Paier B, Skofitsch G, Windisch M.

Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons.

J Neural Transm 2001; 108(4):459-473.

Hetzel H.

Die Wirksamkeit von Gehirnhydrolysaten beim hypoglykaemischen Koma. Münch Med Wochenschr 1954;96(47):1389-1391.

Hetzel H, Niedermeyer E.

Das Gehirnhydrolysat - Weckeffekt im hypoglykaemischen Koma und sein hirnelektrisches Bild. Archiv für Psychiatrie und Zeitschrift für Neurologie 1955;193(4):369-382.

Hoyer S.

Zur Physiologie und Pathophysiologie von Hirndurchblutung und Hirnstoffwechsel. Fortschr Med 1972;90:1235.

Hoyer S.

Zur Wirkungaweise von Cerebrolysin auf das geschaedigte Rattengehirn. Gutachten. 1974.

Hutter-Paier B, Eggenreich U, Windisch M.

Effect of two protein-free peptide derivates on passive avoidance behaviour of 24-month-old rats. Arzneimittelforschung 1996;46;(1):237-241.

Hutter-Paier B, Fruhwirth M, Windisch M.

Ischemia induced loss of MAP2 is prevented by Cerebrolysin and THA. Mol Biol Cell 1996;7:1278-1284.

Hutter-Paier B, Grygar E, Windisch M.

Death of cultured telencephalon neurons induced by glutamate is reduced by the peptide derivative Cerebrolysin.

J Neural Transm Suppl 1996;47:267-273.

Hutter-Paier B, Steiner E, Windisch M.

Cerebrolysin protects isolated cortical neurons from neurodegeneration after brief histotoxic hypoxia. J Neural Transm Supl 1998;53:351-561.

Jellinger KA.

Клинический экспертный доклад о терапевтической эффективности Церебролизина при лечении деменции. Москва 2002. 45 С.

Jonhagen ME, Nordberg A, Amberla K, et al.

Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer’s disease. Dem Geriatr Cogn Disord 1998;9:246-257.

Kofler B, Erhart C, Erhart P, Harrer G.

The usefulness of event-related negativity in demonstrating the therapeutic effects of nootropic drugs using cerebrolysin as an example.

EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb 1990;21 (3):145-149.

Koppi S, Barolin GS.

[Hemodilution therapy with neuron metabolism specific therapy in ischemic stroke - encouraging results of a comparative study].

Wien Med Wochenschr 1996;146(3):41-48.

Koroleva VI, Korolev OS, Mares V, Pastalkova E, Bures J.

Hippocampal damage induced by carbon monoxide poisoning and spreading depression is alleviated by chronic treatment with brain derived polypeptides.

Brain Res 1999;816(2):618-627.

Krammer F.

Behandlung der allgemeinen zerebralen Leistungsschwäche mit Gehirnhydrolysaten im Rahmen von Bäderkuren mit der Schallerbacher Schwefeltherme.

Praktische Arzt 1959;148:649-654.

Ladurner G, Gmeinbauer R, Moessler H.

Cerebrolysin in acute ischemic stroke: a randomized, placebo-control- led clinical trial with a neuroprotective agent.

10-th Europ Stroke Confer Lisbon Portugal: Cer Dis 2001;11(supp 4):75.

Lenz H.

Aminosäuregemisch bei Petit mal und narkoleptischen Anfällen Wien Med Wochenschr 1954; 26/27: 531-532.

Leuschner F.

Toxicological Studies (1980-1992). Internal Reports.

Levi-Montalcini R.

The nerve growth factor: thirty-five years later. EMBO J 1987;6:1145-1154.

Lindner G, Grosse G, Matthies H, Kirsche W.

Effects of brain extract and hydrolysate on nerve tissue in vitro. Z Mikrosk Anat Forsch 1975;89(5):815-823.

Lombardi VR, Windisch M, Garcia M, Cacabelos R.

Effects of Cerebrolysin on in vitro primary microglial and astrocyte rat cell cultures. Methods Find Exp Clin Pharmacol 1999;21(5):331-338.

Mallory M, Honer W, Hsu L, Johnson R, Rockenstein E, Masliah E.

In vitro synaptotrophic effects of Cerebrolysin in NT2N cells. Acta Neuropathol (Berl) 1999;97(5):437-446.

Masliah E, Armasolo F, Veinbergs I, et al.

Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice. Pharmacol Biochem Behav 1999;62(2) : 239-245.

Matula C, Schoeggl A.

Cerebral protection before, during and after neurosurgical procedures. Stereotact Funct Neurosurg 2000;75(2-3):142-146.

Muresanu DF, Rainer M, Moessler H.

Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin.

J Neural Transm Suppl 2002;(62):277-285.

Ono T, Takahashi M, Nakamura Y, Katahira K, Sawamura A, et al.Cerebrolysin injection - one time administration and a repetitive administration test. Internal Report on phase I clinical trial of FPF-1070.1988.

Ono T, Takahashi M, Nakamura Y, Katahira K, Sawamura A, et al.

Phase I study of FPF 1070 (Cerebrolysin) ampouls in healthy volunteers - single and multiple dose study.

Jpn J Pharmacol 1992;20(4):1213-1229.

Palm W.

Cerebrolysin-immunization. Immunization experiments with two bathes of Cerebrolysin, a peptide concentrate and an aqueous powder extract. Expert Report (1989).

Panisset M, Gauthier S, Moessler H, Windisch M.

Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.

J Neural Transm 2002;109(7-8):1089-104.

Petersen I-M, Börop C, Brun B.

Pilotforsog med cerebrolysin til dementer patienter. Nordisk Psykiatrisk Tidsskrift 1979:33,594-598.

Philips MF, Mattiasson G, Wieloch T, Bjorklund A, Johansson BB, et al.

Neuroprotective and behavioral efficacy of NGF-transfected hippocampal progenitor cell transplants after experimental traumatic brain injury.

J Neurosurg 2001;94(5):765-774.

Pruszewicz A, Obrebowski A, Woznica B, Swidzinski P.Pharmacological possibilities in treatment hypoacusis in children. Otolaryngol Pol 1994;48(1):63-66.

Quandt J, Walter L.

Problematic des Cerebrolysineffects bei Neugeborenen.

II. Symposium on Cerebrolysin: Moscow, 1975: 46-49.

Radmayr EP.

Cerebrolysin bei einer unterbegabten Anfallskranken.

Рrakt Arzt 1957; 123:578-581.

Rainer M, Brunnbauer M, Dunky A, et al.

Therapeutic results with Cerebrolysin in the treatment of dementia. Wien Med Wochenschr 1997;147(18):426-431.

Reca T, de Matera C, Taubenschlag H, Kusnir J, Procupet S, Weinstein M.

Vorläufiger Bericht über pharmakologische Versuche (Chemotherapie und biologische Produkte) bei der Behandlung der geistigen Demenz. II. Kongreß für Psychiatrie.1960.

Не нашли, что искали? Воспользуйтесь поиском по сайту: